ObjectiveTo discuss the experiences of video-assisted thoracoscopic surgery (VATS) sleeve lobectomy with bronchoplasty for lung cancer, using only two incisions. MethodWe retrospectively analyzed the clinical data of 16 patients of VATS sleeve lobectomy with bronchoplasty in our hospital between January 2013 and January 2014. There were 14 males and 2 females at age of 55 (39-70) years. The clinical effect was analyzed. ResultsThe patients underwent sleeve lobectomy with bronchoplasty were no severe postoperative complications. Median operative time was 183 min. Median bronchial anastomosis time was 39 min. Median blood loss was 170 ml. The result of pathological examination showed 11 patients with squamous cell carcinomas and 5 patients with adenocarcinoma. Median postoperative chest tube drainage duration was 4.5 days. Median hospital stay was 6.9 days. ConclusionVATS sleeve lobectomy with bronchoplasty is a feasible and safe surgical approach, using only two incisions.
Objective To evaluate the outcomes of sleeve resection following neoadjuvant chemoimmunotherapy for lung cancer. Methods The clinical data of patients diagnosed with lung cancer and undergo sleeve lobectomy surgery at Tianjin Chest Hospital were retrospectively analyzed. Patients were divided into two groups: a neoadjuvant treatment group and a surgery alone group. The clinical data of two groups were compared. Results Finally 22 patients were collected, including 19 males and 3 females with a median age of 63 years. There were 7 patients in the neoadjuvant treatment group, and 15 patients in the surgery alone group. There was no statistical difference in surgical time, intraoperative bleeding, lymph node dissection, postoperative catheterization time, or postoperative drainage volume between the two groups (P>0.05). In the neoadjuvant treatment group, 1 patient had a second thoracotomy exploration for hemostasis due to bronchial artery bleeding, 2 patients had wound infection, 1 patient had immune-associated pneumonia before surgery, and 1 patient had immune-associated pneumonia before postoperative adjuvant therapy. Postoperative pathological results of patients in the neoadjuvant treatment group showed that 1 (1/7, 14.3%) patient had pathological complete response, and 3 (3/7, 42.9%) patients achieved major pathological response. Conclusion Neoadjuvant chemoimmunotherapy can lead to complications, including operation-related complications and immunotherapy-related complications. However, the degree of postoperative pathological remission is also significantly improved. Overall, sleeve resection following neoadjuvant chemoimmunotherapy can be considered as a treatment option for patients with lung cancer.